Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg

Phase 1

Terminated

• Conditions: Healthy
• Interventions: Drug: Olanzapine Tablets 20 mg; Drug: Zyprexa® Tablets 20 mg

• Registration Number: NCT00647972
• Lead Sponsor: Mylan Pharmaceuticals Inc

Brief Summary

The objective of this study was to investigate the bioequivalence of Mylan olanzapine 20 mg tablets to Eli Lilly Zyprexa® 20 mg tablets following a single, oral 20 mg (1 x 20 mg) dose administration under fasting conditions.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-05
• Primary Completion: 2003-05
• Study First Submitted: 2008-03-30
• Study First Submitted QC: 2008-03-31
• Study First Posted: 2008-04-01
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-22
• Last Update Posted: 2024-04-23

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

• healthy, adult subjects, 18 years and older
• able to swallow medication

Exclusion Criteria

• institutionalized subjects
• history of any significant disease
• use of any prescription or OTC medications within 14 days of start of study
• received any investigational products within 30 days prior to start of study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
1	Olanzapine Tablets 20 mg	Olanzapine Tablets 20 mg
2	Zyprexa® Tablets 20 mg	Zyprexa® Tablets 20 mg

Primary Outcome Measures

Name	Time	Method
The 90% confidence interval for the LSMeans ratio of CPEAK, AUCL, and AUCI for the test and reference product should be between 80.00% and 125.00% for the natural log-transformed data.	blood collections through 144 hours

Trial Locations

Locations (1)

Kendle International Inc.; 🇺🇸 Morgantown, West Virginia, United States